- 1
Post-market surveillance, end to end
What FDA expects you to monitor, document, and trend after clearance.
- 2
Adverse event reporting (MDR)
When you must report, what counts as MDR-reportable, the 30-day and 5-day clocks.
- 3
Inspections and Form 483
Front-room/back-room playbook, the 483 response window, and what 'not committing' really means.
- 4
Warning letters - prevent, decode, respond
Reading FDA's signal, drafting the response, and the operational fixes that close the file.
- 5
Recalls - classification and crisis prevention
Class I, II, III recalls. When to recall voluntarily. What FDA sees first.
- 6
The QMSR transition (Feb 2026)
What changes under QMSR, what stays, and the gap analysis you need to run now.
You finished the Post-Market Track.
Want to keep going? Browse every explainer tagged for this track, or jump into another path.
Try another path
Founder Track
From device idea to documented FDA strategy
RA Lead Track
Standardize how your team writes 510(k)s, risk files, and design history files
SaMD & AI Track
For software and AI/ML medical device teams navigating CDRH's evolving guidance
International Track
Enter the US market from abroad. The whole pathway, in plain English.